{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:54:34Z","timestamp":1792652074372,"version":"4.5.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.blre.2025.101288","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:20:40Z","timestamp":1744165240000},"page":"101288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy"],"prefix":"10.1016","volume":"73","author":[{"given":"Raffaele","family":"Palmieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Candoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Volpicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Finsinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morena","family":"Caira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicetto","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.blre.2025.101288_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101288_bb0010","series-title":"NCCN Clinical Practice Guidelines in Oncology - Acute Myeloid Leukemia. Version 1.2025 \u2014 December 20, 2024Version 2.2023","author":"NCCN","year":"2024"},{"key":"10.1016\/j.blre.2025.101288_bb0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101288_bb0020","author":"AIOM"},{"issue":"18","key":"10.1016\/j.blre.2025.101288_bb0025","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute leukemia registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2025.101288_bb0030","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101288_bb0035","unstructured":"EMA. EMA summary of product characteristics - OnuregEMA."},{"issue":"9","key":"10.1016\/j.blre.2025.101288_bb0040","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101288_bb0045","unstructured":"EMA. Summary of product characteristics - Gemtuzumab ozogamicinEMA."},{"key":"10.1016\/j.blre.2025.101288_bb0050","unstructured":"EMA. Summary of product characteristics \u2013 VyxeosEMA."},{"issue":"11","key":"10.1016\/j.blre.2025.101288_bb0055","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s11912-022-01299-9","article-title":"Older patients with Acute myeloid leukemia deserve individualized treatment","volume":"24","author":"de Leeuw","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1016\/j.blre.2025.101288_bb0060","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/bjh.17213","article-title":"Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study","volume":"193","author":"Hjort Jakobsen","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2025.101288_bb0065","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1007\/s00432-021-03756-7","article-title":"Patterns of undertreatment among patients with acute myeloid leukemia (AML): considerations for patients eligible for non-intensive chemotherapy (NIC)","volume":"147","author":"Hubscher","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2025.101288_bb0070","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1080\/10428194.2021.2012666","article-title":"Treatment patterns, economic burden, and overall survival in US Medicare advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015-2020","volume":"63","author":"Huntington","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.blre.2025.101288_bb0075","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/10428194.2021.1973669","article-title":"Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy","volume":"63","author":"Li","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.blre.2025.101288_bb0080","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.clml.2016.08.006","article-title":"An evaluation of treatment patterns and outcomes in elderly patients newly diagnosed with Acute myeloid leukemia: a retrospective analysis of electronic medical records from US Community oncology practices","volume":"16","author":"Ma","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.blre.2025.101288_bb0085","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/s41375-020-01058-4","article-title":"Evolving treatment patterns and outcomes in older patients (\u226560 years) with AML: changing everything to change nothing?","volume":"35","author":"Mart\u00ednez-Cuadr\u00f3n","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2025.101288_bb0090","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101288_bb0095","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1080\/10428194.2021.2002321","article-title":"Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy","volume":"63","author":"Miyamoto","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.blre.2025.101288_bb0100","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3324\/haematol.2018.208637","article-title":"Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia","volume":"105","author":"Talati","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.blre.2025.101288_bb0105","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1159\/000531628","article-title":"Acute myeloid leukemia treatment in the elderly: a comprehensive review of the present and future","volume":"146","author":"Choi","year":"2023","journal-title":"Acta Haematol"},{"issue":"6","key":"10.1016\/j.blre.2025.101288_bb0110","doi-asserted-by":"crossref","first-page":"296","DOI":"10.5694\/mja2.51423","article-title":"Changes in five-year survival for people with acute leukaemia in South Australia, 1980-2016","volume":"216","author":"Beckmann","year":"2022","journal-title":"Med J Aust"},{"key":"10.1016\/j.blre.2025.101288_bb0135","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","article-title":"Myeloid malignancies in the real-world: occurrence, progression and survival in the UK\u2019S population-based Haematological malignancy research network 2004-15","volume":"42","author":"Roman","year":"2016","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"10.1016\/j.blre.2025.101288_bb0140","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/03008916231153698","article-title":"Acute myeloid leukemia: incidence, transplantation and survival through Italian administrative healthcare data","volume":"109","author":"Calabria","year":"2023","journal-title":"Tumori"},{"issue":"11","key":"10.1016\/j.blre.2025.101288_bb0115","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1007\/s00277-021-04631-8","article-title":"Long-term trends in the clinical outcomes of patients with acute myeloid leukemia: a population-based real-world data analysis using the Osaka Cancer registry","volume":"100","author":"Fuji","year":"2021","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.blre.2025.101288_bb0120","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/imj.12169","article-title":"Acute myeloid leukaemia in Western Australia 1991-2005: a retrospective population-based study of 898 patients regarding epidemiology, cytogenetics, treatment and outcome","volume":"43","author":"Gangatharan","year":"2013","journal-title":"Intern Med J"},{"issue":"31","key":"10.1016\/j.blre.2025.101288_bb0125","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related Acute myeloid leukemia: a National Population-Based Cohort Study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2025.101288_bb0130","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3109\/10428194.2015.1108413","article-title":"Incidence and outcomes for adults diagnosed with acute myeloid leukemia in the north of England: a real world study","volume":"57","author":"McGregor","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.blre.2025.101288_bb0145","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1080\/10428194.2022.2045593","article-title":"Incidence of myeloid malignancies by subtype in Hong Kong and comparisons with Asian and white men and women in the United States","volume":"63","author":"Bassig","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.blre.2025.101288_bb0150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hon.733","article-title":"Hematological malignancies in the island of Sardinia, 1974-1993: age and sex distributions and temporal changes in incidence","volume":"22","author":"Broccia","year":"2004","journal-title":"Hematol Oncol"},{"issue":"1 Suppl 2","key":"10.1016\/j.blre.2025.101288_bb0155","first-page":"1","article-title":"Italian cancer figures--Report 2015: The burden of rare cancers in Italy","volume":"40","author":"Busco","year":"2016","journal-title":"Epidemiol Prev"},{"issue":"1","key":"10.1016\/j.blre.2025.101288_bb0160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12889-017-4644-6","article-title":"The incidence of acute myeloid leukemia in Calgary, Alberta, Canada: a retrospective cohort study","volume":"18","author":"Shysh","year":"2017","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.blre.2025.101288_bb0165","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41598-021-03734-6","article-title":"Incidence of myeloid neoplasms in Spain (2002\u22122013): a population-based study of the Spanish network of cancer registries","volume":"12","author":"Solans","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.blre.2025.101288_bb0170","first-page":"296","article-title":"Survival of elderly patients with acute myeloid leukemia","volume":"89","author":"Pulsoni","year":"2004","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.blre.2025.101288_bb0175","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.958.958","article-title":"Prevalence and incidence of Acute myeloid leukemia may be higher than currently accepted estimates among the \u226565 year-old population in the United States","volume":"124","author":"Turbeville","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101288_bb0180","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-020-00170-6","article-title":"Leukemia incidence trends at the global, regional, and national level between 1990 and 2017","volume":"9","author":"Dong","year":"2020","journal-title":"Exp Hematol Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2025.101288_bb0185","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/0284186X.2015.1115124","article-title":"Trends in hematological cancer in the elderly in Denmark, 1980-2012","volume":"55","author":"Ocias","year":"2016","journal-title":"Acta Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101288_bb0195","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jfma.2022.10.007","article-title":"Epidemiology and survival outcomes of acute myeloid leukemia patients in Taiwan: a national population-based analysis from 2001 to 2015","volume":"122","author":"Chien","year":"2023","journal-title":"J Formos Med Assoc"},{"issue":"2 Suppl 1","key":"10.1016\/j.blre.2025.101288_bb0200","first-page":"1","article-title":"Survival of cancer patients in Italy","volume":"41","author":"Coviello","year":"2017","journal-title":"Epidemiol Prev"},{"issue":"1","key":"10.1016\/j.blre.2025.101288_bb0205","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bjh.13406","article-title":"Acute myeloid leukaemia: challenges and real world data from India","volume":"170","author":"Philip","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101288_bb0210","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.2019001728","article-title":"Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period","volume":"134","author":"Juliusson","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2025.101288_bb0215","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101288_bb0220","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.canep.2017.11.008","article-title":"Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013","volume":"52","author":"Schnegg-Kaufmann","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"17","key":"10.1016\/j.blre.2025.101288_bb0515","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1182\/bloodadvances.2023010173","article-title":"Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting","volume":"7","author":"Attardi","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2025.101288_bb0525","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/030089160909500306","article-title":"Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland","volume":"95","author":"Lerch","year":"2009","journal-title":"Tumori"},{"key":"10.1016\/j.blre.2025.101288_bb0535","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/leu.2016.312","article-title":"Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden","volume":"31","author":"Juliusson","year":"2017","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.blre.2025.101288_bb0540","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2025.101288_bb0545","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","article-title":"Incidence, survival and prevalence of myeloid malignancies in Europe","volume":"48","author":"Visser","year":"2012","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.blre.2025.101288_bb0550","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000486228","article-title":"Incidence, survival, and risk factors for adults with Acute myeloid leukemia not otherwise specified and Acute myeloid leukemia with recurrent genetic abnormalities: analysis of the surveillance, epidemiology, and end results (SEER) database, 2001-2013","volume":"139","author":"Song","year":"2018","journal-title":"Acta Haematol"},{"issue":"11","key":"10.1016\/j.blre.2025.101288_bb0555","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/cncr.32034","article-title":"Analysis of acute myeloid leukemia incidence and geographic distribution in Canada from 1992 to 2010 reveals disease clusters in Sarnia and other industrial US border cities in Ontario","volume":"125","author":"Ghazawi","year":"2019","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.blre.2025.101288_bb0560","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1080\/10428190701713622","article-title":"Estimated number of cases, regional distribution and survival of patients diagnosed with acute myeloid leukemia between 1996 and 2000 in Rio Grande do Sul, Brazil","volume":"48","author":"Capra","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.blre.2025.101288_bb0565","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5144\/1658-3876.2011.161","article-title":"A population-based study of the epidemiology and clinical features of adults with acute myeloid leukemia in Algeria: report on behalf of the Algerian Acute leukemia study group","volume":"4","author":"Bekadja","year":"2011","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.blre.2025.101288_bb0570","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.canep.2018.01.016","article-title":"Incidence of haematological malignancies, eastern Cape Province; South Africa, 2004-2013","volume":"53","author":"Oelofse","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.blre.2025.101288_bb0575","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12185-012-1146-2","article-title":"Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki prefecture, Japan","volume":"96","author":"Matsunaga","year":"2012","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101288_bb0580","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261871","article-title":"The epidemiology, treatment patterns, healthcare utilizations and costs of Acute myeloid Leukaemia (AML) in Taiwan","volume":"17","author":"Huang","year":"2022","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.blre.2025.101288_bb0585","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1016\/j.clml.2021.03.004","article-title":"Types, clinical features, and survival outcomes of patients with Acute myeloid leukemia in Thailand: a 3-year prospective multicenter study from the Thai Acute leukemia study group (TALSG)","volume":"21","author":"Wanitpongpun","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.blre.2025.101288_bb0590","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000524641","article-title":"Epidemiology of de novo Acute myeloid leukemia in Kuwait per the 2016 WHO classification","volume":"31","author":"Alshemmari","year":"2022","journal-title":"Med Princ Pract"},{"issue":"12","key":"10.1016\/j.blre.2025.101288_bb0595","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.31557\/APJCP.2022.23.12.4163","article-title":"Epidemiological features of Acute myeloid leukemia in five regions of the Republic of Kazakhstan: population study","volume":"23","author":"Aitbekov","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"issue":"11","key":"10.1016\/j.blre.2025.101288_bb0600","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.31557\/APJCP.2022.23.11.3869","article-title":"Incidence and risk factors of Acute Leukemias in Armenia: a population-based study","volume":"23","author":"Khondkaryan","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"10.1016\/j.blre.2025.101288_bb0190","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"issue":"20","key":"10.1016\/j.blre.2025.101288_bb0225","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2025.101288_bb0230","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2025.101288_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010120","article-title":"Therapeutic choice in older patients with Acute myeloid leukemia: a matter of fitness","volume":"12","author":"Palmieri","year":"2020","journal-title":"Cancers"},{"issue":"21","key":"10.1016\/j.blre.2025.101288_bb0240","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"Dohner","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2025.101288_bb0235","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101288_bb0250","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.2023022611","article-title":"Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action","volume":"143","author":"Bhatt","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101288_bb0255","first-page":"2024013744","article-title":"Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of European leukemia net","author":"Venditti","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2025.101288_bb0260","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/17474086.2023.2185603","article-title":"Assessing eligibility for treatment in acute myeloid leukemia in 2023","volume":"16","author":"Venditti","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101288_bb0265","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0889-8588(05)70287-2","article-title":"Acute myelogenous leukemia and aging. Clinical interactions","volume":"14","author":"Lancet","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"10.1016\/j.blre.2025.101288_bb0270","first-page":"1502","article-title":"Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia","volume":"90","author":"Bacher","year":"2005","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2025.101288_bb0285","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1200\/JCO.1994.12.3.601","article-title":"Prospective evaluation of prognostic variables from patient-completed questionnaires. North central Cancer treatment group","volume":"12","author":"Loprinzi","year":"1994","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2025.101288_bb0280","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2352-3026(18)30132-7","article-title":"Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial","volume":"5","author":"Kadia","year":"2018","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.blre.2025.101288_bb0290","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/14656566.2018.1465562","article-title":"Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia","volume":"19","author":"Michaelis","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.blre.2025.101288_bb0295","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"21","key":"10.1016\/j.blre.2025.101288_bb0300","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2025.101288_bb0305","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1532-5415.2011.03614.x","article-title":"The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"59","author":"Klepin","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.blre.2025.101288_bb0310","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2025.101288_bb0315","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2020008812","article-title":"Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia","volume":"138","author":"Sorror","year":"2021","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.blre.2025.101288_bb0320","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","article-title":"Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2025.101288_bb0325","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jgo.2020.10.004","article-title":"Validation of the \u201cfitness criteria\u201d for the treatment of older patients with acute myeloid leukemia: a multicenter study on a series of 699 patients by the network rete Ematologica Lombarda (REL)","volume":"12","author":"Borlenghi","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.blre.2025.101288_bb0330","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1182\/blood-2019-127873","article-title":"Validation of SIE, Sies, GITMO operational criteria for the definition of fitness in elderly patients affected with acute myeloid leukemia: a six-years retrospective real-life experience","volume":"134","author":"Palmieri","year":"2019","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.blre.2025.101288_bb0335","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1200\/JCO.20.01392","article-title":"Accuracy of SIE\/SIES\/GITMO consensus criteria for unfitness to predict early mortality after intensive chemotherapy in adults with AML or other high-grade myeloid neoplasm","volume":"38","author":"Palmieri","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2025.101288_bb0340","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in previously untreated Acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2025.101288_bb0345","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101288_bb0350","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41408-022-00668-8","article-title":"Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia","volume":"12","author":"Pratz","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.blre.2025.101288_bb0355","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.blre.2025.101288_bb0360","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101288_bb0365","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/10428194.2023.2197090","article-title":"Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data","volume":"64","author":"Hoff","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"10.1016\/j.blre.2025.101288_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184618","article-title":"Venetoclax with Hypomethylating agents in newly diagnosed Acute myeloid leukemia: a systematic review and Meta-analysis of survival data from real-world studies","volume":"15","author":"Ucciero","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.blre.2025.101288_bb0375","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.27231","article-title":"Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75years and older with acute myeloid leukemia: real-world data from eight US academic centers","volume":"99","author":"Abaza","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101288_bb0380","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2023-178505","article-title":"Real world outcome of unfit patients with Acute myeloid leukemia treated with the combination Venetoclax plus Hypomethylating agents in the Gimema AML2320 observational trial","volume":"142","author":"Venditti","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101288_bb0390","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2025.101288_bb0395","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00277-021-04465-4","article-title":"Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial","volume":"100","author":"Heuser","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2025.101288_bb0400","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1182\/blood-2024-206787","article-title":"Association of Glasdegib+ low-dose Cytarabine (AraC) in the real-life treatment of very frail elderly Acute myeloid Leukemias (AML) patients","volume":"144","author":"Tanasi","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101288_bb0405","author":"SIE"},{"key":"10.1016\/j.blre.2025.101288_bb0410","unstructured":"EMA. Product overview \u2013 Inaqovi EMA."},{"issue":"16","key":"10.1016\/j.blre.2025.101288_bb0415","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-mutated Acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101288_bb0420","series-title":"Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine","author":"De Botton","year":"2023"},{"issue":"7","key":"10.1016\/j.blre.2025.101288_bb0425","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101288_bb0430","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood-2024-210603","article-title":"Outcomes by frailty in IC-ineligible newly diagnosed AML-a real-world evidence comparison by treatment with Hypomethylating agents+ Ivosidenib or Venetoclax","volume":"144","author":"Smith","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101288_bb0435","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1182\/blood-2022-160002","article-title":"Real-world treatment patterns and transfusion burden among newly diagnosed older adults with Acute myeloid leukemia","volume":"140","author":"Zeidan","year":"2022","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2025.101288_bb0440","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143589","article-title":"Building on foundations: Venetoclax-based combinations in the treatment of Acute myeloid leukemia","volume":"15","author":"Oyogoa","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101288_bb0445","author":"CancerNetwork"},{"key":"10.1016\/j.blre.2025.101288_bb0450","series-title":"Gilead discontinues phase 3 ENHANCE 2 trial of magrolimab plus azacitidine in TP53-mutant AML","author":"OncLive","year":"2023"},{"issue":"21","key":"10.1016\/j.blre.2025.101288_bb0455","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1002\/cncr.32904","article-title":"Treating acute myeloid leukemia in the modern era: a primer","volume":"126","author":"Blum","year":"2020","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.blre.2025.101288_bb0460","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2217\/fon-2022-0786","article-title":"Elderly patients with acute myeloid leukemia who only receive supportive care in the surveillance, epidemiology and end results-Medicare database: demographics, treatment patterns and outcomes","volume":"19","author":"Dharmani","year":"2023","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.blre.2025.101288_bb0465","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/COC.0b013e3181dea934","article-title":"Effects of poverty and race on outcomes in acute myeloid leukemia","volume":"34","author":"Byrne","year":"2011","journal-title":"Am J Clin Oncol"},{"issue":"20","key":"10.1016\/j.blre.2025.101288_bb0470","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/cncr.30183","article-title":"Impact of marital status, insurance status, income, and race\/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States","volume":"122","author":"Costa","year":"2016","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.blre.2025.101288_bb0475","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood.V126.23.3316.3316","article-title":"Impact of socioeconomic, demographic and health system factors on therapy in acute myeloid leukemia","volume":"126","author":"Goyal","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101288_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101631","article-title":"New treatment opportunities for older patients with acute myeloid leukemia and the increasing importance of frailty assessment - an oncogeriatric perspective","volume":"15","author":"Diekmann","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.blre.2025.101288_bb0485","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020386","volume":"16","author":"Rossi","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2025.101288_bb0490","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood-2023-189800","article-title":"Treatment outcomes in unfit patients with newly Acute myeloid leukemia according to IDH1 mutational status: real world evidence from the Pethema epidemiologic registry","volume":"142","author":"Martinez-Cuadron","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2025.101288_bb0495","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.26991","article-title":"Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia","volume":"98","author":"Matthews","year":"2023","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.blre.2025.101288_bb0500","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101288_bb0505","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2023-173033","article-title":"A comparison of Acute myeloid leukemia (AML) regimens: Hypomethylating agents combined with Ivosidenib or Venetoclax in newly diagnosed patients with IDH1 mutations: a real-world evidence study","volume":"142","author":"Smith","year":"2023","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2025.101288_bb0520","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101288_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101238","article-title":"Ven the dose matters: Venetoclax dosing in the frontline treatment of AML","volume":"68","author":"Sastow","year":"2024","journal-title":"Blood Rev"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T14:26:27Z","timestamp":1755959187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":117,"alternative-id":["S0268960X25000335"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101288","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101288"}}